Abstract
During the past decade, radiolabeled receptor-binding peptides have emerged as an important class of radiopharmaceuticals for tumor diagnosis and therapy. The specific receptor binding property of the ligand can be exploited by labeling the ligand with a radionuclide and using the radiolabeled ligand as a vehicle to guide the radioactivity to the tissues expressing a particular receptor. The concept of using radiolabeled receptor binding peptides to target receptor-expressing tissues in vivo has stimulated a large body of research in nuclear medicine. Receptor binding peptides labeled with gamma emitters (123I, 111In, 99mTc) can visualize receptor-expressing tissues, a technique referred to as peptide-receptor radionuclide imaging (PRRI). In addition, labeled with beta emitters (131I, 90Y, 188Re, 177Lu) these peptides have the potential to irradiate receptor-expressing tissues, an approach referred to as peptide-receptor radionuclide therapy (PRRT). The first and most succesful imaging agent to date is the somatostatin analog octreotide. It is used for somatostatin receptor scintigraphy and PRRT of neuroendocrine tumors. Other peptides such as Minigastrin, GLP-1, CCK, bombesin, substance P, neurotensin, and RGD peptides are currently under development or undergoing clinical trials. In this review, an overview of the criteria of peptide ligand development, the selection of radioisotopes, labeling methods, and chemical aspects of radiopeptide synthesis is given. In addition, the current state of clinical use of radiopeptides for diagnosis and therapy of tumors is discussed.
Keywords: Peptides, chelators, radionuclides, radiolabeling, tumor targeting, imaging, radionuclide therapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Development and Application of Peptide-Based Radiopharmaceuticals
Volume: 7 Issue: 5
Author(s): Ingrid Dijkgraaf, Otto C. Boerman, Wim J.G. Oyen, Frans H.M. Corstens and Martin Gotthardt
Affiliation:
Keywords: Peptides, chelators, radionuclides, radiolabeling, tumor targeting, imaging, radionuclide therapy
Abstract: During the past decade, radiolabeled receptor-binding peptides have emerged as an important class of radiopharmaceuticals for tumor diagnosis and therapy. The specific receptor binding property of the ligand can be exploited by labeling the ligand with a radionuclide and using the radiolabeled ligand as a vehicle to guide the radioactivity to the tissues expressing a particular receptor. The concept of using radiolabeled receptor binding peptides to target receptor-expressing tissues in vivo has stimulated a large body of research in nuclear medicine. Receptor binding peptides labeled with gamma emitters (123I, 111In, 99mTc) can visualize receptor-expressing tissues, a technique referred to as peptide-receptor radionuclide imaging (PRRI). In addition, labeled with beta emitters (131I, 90Y, 188Re, 177Lu) these peptides have the potential to irradiate receptor-expressing tissues, an approach referred to as peptide-receptor radionuclide therapy (PRRT). The first and most succesful imaging agent to date is the somatostatin analog octreotide. It is used for somatostatin receptor scintigraphy and PRRT of neuroendocrine tumors. Other peptides such as Minigastrin, GLP-1, CCK, bombesin, substance P, neurotensin, and RGD peptides are currently under development or undergoing clinical trials. In this review, an overview of the criteria of peptide ligand development, the selection of radioisotopes, labeling methods, and chemical aspects of radiopeptide synthesis is given. In addition, the current state of clinical use of radiopeptides for diagnosis and therapy of tumors is discussed.
Export Options
About this article
Cite this article as:
Dijkgraaf Ingrid, Boerman C. Otto, Oyen J.G. Wim, Corstens H.M. Frans and Gotthardt Martin, Development and Application of Peptide-Based Radiopharmaceuticals, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (5) . https://dx.doi.org/10.2174/187152007781668733
DOI https://dx.doi.org/10.2174/187152007781668733 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Aspects of Natural and Modified Vinca Alkaloids
Current Medicinal Chemistry - Anti-Cancer Agents Clinical Pharmacogenetics of Methotrexate
Current Drug Metabolism Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review
Current Medical Imaging A Classification Method for Microarrays Based on Diversity
Current Bioinformatics Vitamin D and miRNAs in Cancer
Current Gene Therapy Phosphoinositide 3-Kinases as Targets for Therapeutic Intervention
Current Pharmaceutical Design Phosphoregulation of Twist1 Provides a Mechanism of Cell Fate Control
Current Medicinal Chemistry An Overview of Current Screening and Management Approaches for Prostate Cancer
Current Drug Metabolism Preface
Current Proteomics PEGylated Lipid Nanocapsules with Improved Drug Encapsulation and Controlled Release Properties
Current Topics in Medicinal Chemistry Toward the Identification of Novel Carbonic Anhydrase XIV Inhibitors using 3D-QSAR Pharmacophore Model, Virtual Screening and Molecular Docking Study
Letters in Drug Design & Discovery Proteomic Analysis of Medicinal Plant <i>Calotropis Gigantea</i> by <i>In Silico</i> Peptide Mass Fingerprinting
Current Computer-Aided Drug Design Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Vinorelbine in the Treatment of Non-Small Cell Lung Cancer
Current Medicinal Chemistry Development and Validation of a Simple LC-UV Method to Assay Doxazosin in Polymeric Nanocapsules and Tablets
Current Pharmaceutical Analysis G Protein-Coupled Receptors – Potential Roles in Clinical Pharmacology
Cardiovascular & Hematological Agents in Medicinal Chemistry Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening Atrial Fibrillation in Heart Failure: An Innocent Bystander?
Current Cardiology Reviews Evaluation of Melatonin Effect on Human Breast Cancer Stem Cells Using a Threedimensional Growth Method of Mammospheres
Anti-Cancer Agents in Medicinal Chemistry Emerging Opportunities and Concerns for Drug Discovery at Serotonin 5-5-HT2B Receptors
Current Topics in Medicinal Chemistry